Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07145255 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by MBrace Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 7
- Study locations
NCT07145255: Recruiting Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by MBrace Therapeutics.
NCT07145255 is a Phase 1 study of Breast Cancer and Colorectal Cancer that is actively recruiting participants, run by MBrace Therapeutics. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07145255, a Phase 1 study of Breast Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by MBrace Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Primary Outcome
• TEAEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.5.0.
Conditions Studied
Interventions
- DRUG ADC
Study Locations (7)
Texas
- NEXT, Dallas - Irving
- START San Antonio - San Antonio
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Michigan
- START, Midwest - Grand Rapids
New Jersey
- START, Astera - East Brunswick
Utah
- START, Mountain Region - West Valley City
Virginia
- NEXT, Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 1 |
What NCT07145255 shows while recruiting
NCT07145255 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ADC is the first listed.
NCT07145255 lists 7 locations in 6 states (Texas, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT07145255 about?
NCT07145255 is a clinical study titled "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors". This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
What is the current status of trial NCT07145255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-09-03. Estimated completion is 2029-12-30.
What conditions does trial NCT07145255 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Non-Small Cell, Prostate Cancer Castration-resistant Prostate Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma.
What interventions are being tested in trial NCT07145255?
The interventions under investigation include: ADC (DRUG).
Who is sponsoring clinical trial NCT07145255?
This trial is sponsored by MBrace Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07145255 being conducted?
This trial has 7 study locations across California, Michigan, New Jersey, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07145255's enrollment target sits among peer trials
150 444th of 1224 higher than 772 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI